SCHEMBL16092976

SCHEMBL16092976

[N-]=[N+]=N[C@@H](Cc1ccc([N+](=O)[O-])cc1)C(N)=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.45
▸ MAPT P10636 5/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ HTT P42858 4/20 0.43
▸ POLB P06746 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ IDO1 P14902 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ TSHR P16473 2/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ CRHBP P24387 1/20 0.41
▸ CRHR2 Q13324 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16788844 1.00 ALDH1A1 (0.45) ALDH1A1MAPTKMT2AMEN1HTT
SCHEMBL16092975 0.87 CYP2C19 (0.44) ALDH1A1MAPTKMT2AMEN1HTT
SCHEMBL16788843 0.87 CYP2C19 (0.44) ALDH1A1MAPTKMT2AMEN1HTT
SCHEMBL30151424 0.87 EPHX1 (0.40) EPHX1
SCHEMBL14270257 0.86 LMNA (0.45) ALDH1A1MAPTKMT2AMEN1HTT
SCHEMBL16092968 0.83 GAA (0.43) ALDH1A1MAPTKMT2AMEN1HTT
SCHEMBL14270273 0.83 GAA (0.43) ALDH1A1MAPTKMT2AMEN1HTT
SCHEMBL16788856 0.83 PSMB2 (0.35) —
SCHEMBL16092972 0.79 CA2 (0.46) MAPTL3MBTL1SMN1; SMN2
SCHEMBL14270308 0.79 CA2 (0.46) MAPTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841263-B2 Macrocyclic compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2014-09-23 — — US disclosed
US-20120252747-A1 MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME SILICON VALLEY BANK 2012-10-04 — — US disclosed
US-8202843-B2 Macrocyclic compounds and methods of making and using the same RIB-X PHARMACEUTICALS, INC. (US) 2012-06-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252747-A1 MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME CCNO, PTGDR, CCNE1 ALDH1A1 2970/4885MAPT 4552/4885KMT2A 4556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback